<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931527</url>
  </required_header>
  <id_info>
    <org_study_id>06-0509 / 201104189</org_study_id>
    <nct_id>NCT01931527</nct_id>
  </id_info>
  <brief_title>Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status</brief_title>
  <acronym>UA</acronym>
  <official_title>Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about what is the effect of uric acid on oxidative
      stress and on the way the body metabolizes sugar in obese people. Understanding this may lead
      to better diseases such as diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been hypothesized that oxidative stress is involved in the pathogenesis of insulin
      resistance associated with obesity. Circulating uric acid (UA) is the body's major endogenous
      plasma antioxidant. Therefore, the investigators evaluated whether alterations in serum UA
      concentration affect: 1) systemic and skeletal muscle oxidative stress, 2) total antioxidant
      capacity, and 4) skeletal muscle insulin sensitivity during a hyperinsulinemic-euglycemic
      clamp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Increase in Insulin-stimulated Glucose Uptake</measure>
    <time_frame>12 hours after reducing uric acid</time_frame>
    <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure percent increase in insulin-stimulated glucose uptake in obese subjects with high uric acid before and after uric acid reduction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of Reducing Uric Acid on Oxidative Status</measure>
    <time_frame>12 hours after reducing uric acid</time_frame>
    <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma TRAP and FRAP) will be measured in obese subjects with high uric acid before and after uric acid reduction. Levels of isoprostanes were normalized to urinary creatinine and reported at ng/mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Carbonylated Protein Ratio</measure>
    <time_frame>Before reducing uric acid</time_frame>
    <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFTER Rasburicase Carbonylated Protein Ratio</measure>
    <time_frame>12 hours after reducing uric acid</time_frame>
    <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Plasma TRAP</measure>
    <time_frame>Before reducing uric acid</time_frame>
    <description>Total Radical-Trapping Antioxidant Potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFTER Rasburicase Plasma TRAP</measure>
    <time_frame>12 hours after reducing uric acid</time_frame>
    <description>Total Radical-Trapping Antioxidant Potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Plasma FRAP</measure>
    <time_frame>Before reducing uric acid</time_frame>
    <description>Ferric-Reducing Antioxidant Potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFTER Rasburicase Plasma FRAP (Fe⁺² · Lˉ¹)</measure>
    <time_frame>12 hours after reducing uric acid</time_frame>
    <description>Ferric-Reducing Antioxidant Potential</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Obese subjects with normal uric acid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with a body mass index = or &gt; 30 kg/m² with normal uric acid (= or &lt; 5 mg/dL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese subjects with high uric acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a body mass index = or &gt; 30 kg/m² with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase</intervention_name>
    <description>one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
    <arm_group_label>Obese subjects with high uric acid</arm_group_label>
    <other_name>Elitek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  obese (BMI 30-45 kg/m²);

          -  serum UA concentration either ≥5 mg/dL or ≤4.0 mg/dL (297 µmol/L)],

        Exclusion Criteria:

          -  renal dysfunction (serum creatinine &gt;1.5 mg/dL);

          -  pregnancy or lactating;

          -  take urate-lowering agents, thiazide diuretics, prednisone or medications containing
             aspirin or other salicylates;

          -  history of xanthinuria, type 2 diabetes or other significant organ system dysfunction;

          -  have G6PD deficiency;

          -  use hormone-replacement or oral-contraceptive therapy;

          -  smoke tobacco;

          -  anemic (Hb &lt;10 g/dl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>April 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2015</results_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Hyperuricemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Obese Subjects With Normal Uric Acid</title>
          <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
        </group>
        <group group_id="P2">
          <title>Obese Subjects With High Uric Acid</title>
          <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Obese subjects with low uric acid (&lt;5mg/dL)</population>
      <group_list>
        <group group_id="B1">
          <title>Low Uric Acid</title>
          <description>16 obese subjects (BMI 37.1±0.7 kg/m2) with uric acid &lt;5mg/dL</description>
        </group>
        <group group_id="B2">
          <title>High Uric Acid</title>
          <description>15 obese subjects (BMI 37.1±0.7 kg/m2) with uric acid &gt;6mg/dL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="3.2"/>
                    <measurement group_id="B2" value="38.3" spread="4.8"/>
                    <measurement group_id="B3" value="37.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma uric acid concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.2"/>
                    <measurement group_id="B2" value="7.1" spread="1.6"/>
                    <measurement group_id="B3" value="5.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Increase in Insulin-stimulated Glucose Uptake</title>
        <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure percent increase in insulin-stimulated glucose uptake in obese subjects with high uric acid before and after uric acid reduction.</description>
        <time_frame>12 hours after reducing uric acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m^2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m^2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Increase in Insulin-stimulated Glucose Uptake</title>
          <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure percent increase in insulin-stimulated glucose uptake in obese subjects with high uric acid before and after uric acid reduction.</description>
          <units>% incr. in insulin-mediated gluc. uptake</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASAL Insulin Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="23"/>
                    <measurement group_id="O2" value="162" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFTER RASBURICASE Insulin Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Rasburicase infusion to lower uric acid was only administered to subjects in the High Uric Acid group</measurement>
                    <measurement group_id="O2" value="156" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Reducing Uric Acid on Oxidative Status</title>
        <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma TRAP and FRAP) will be measured in obese subjects with high uric acid before and after uric acid reduction. Levels of isoprostanes were normalized to urinary creatinine and reported at ng/mg.</description>
        <time_frame>12 hours after reducing uric acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m^2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m^2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Reducing Uric Acid on Oxidative Status</title>
          <description>Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma TRAP and FRAP) will be measured in obese subjects with high uric acid before and after uric acid reduction. Levels of isoprostanes were normalized to urinary creatinine and reported at ng/mg.</description>
          <units>ng/mg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE urinary isoprostanes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.15"/>
                    <measurement group_id="O2" value="0.68" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AFTER RASBURICASE isoprostanes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Rasburicase infusion to reduce uric acid was administered only to the High Uric Acid group</measurement>
                    <measurement group_id="O2" value="0.96" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Carbonylated Protein Ratio</title>
        <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
        <time_frame>Before reducing uric acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Carbonylated Protein Ratio</title>
          <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="929" spread="86"/>
                    <measurement group_id="O2" value="680" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AFTER Rasburicase Carbonylated Protein Ratio</title>
        <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
        <time_frame>12 hours after reducing uric acid</time_frame>
        <population>Analysis only completed on subjects in the High Uric Acid group</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>AFTER Rasburicase Carbonylated Protein Ratio</title>
          <description>Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle</description>
          <population>Analysis only completed on subjects in the High Uric Acid group</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1085" spread="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Plasma TRAP</title>
        <description>Total Radical-Trapping Antioxidant Potential</description>
        <time_frame>Before reducing uric acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Plasma TRAP</title>
          <description>Total Radical-Trapping Antioxidant Potential</description>
          <units>mmol · Lˉ¹</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.02"/>
                    <measurement group_id="O2" value="1.31" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AFTER Rasburicase Plasma TRAP</title>
        <description>Total Radical-Trapping Antioxidant Potential</description>
        <time_frame>12 hours after reducing uric acid</time_frame>
        <population>AFTER rasburicase plasma Total Radical-Trapping Antioxidant Potential (TRAP) was only measured in the subjects with high uric acid</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>AFTER Rasburicase Plasma TRAP</title>
          <description>Total Radical-Trapping Antioxidant Potential</description>
          <population>AFTER rasburicase plasma Total Radical-Trapping Antioxidant Potential (TRAP) was only measured in the subjects with high uric acid</population>
          <units>mmol · Lˉ¹</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.71" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Plasma FRAP</title>
        <description>Ferric-Reducing Antioxidant Potential</description>
        <time_frame>Before reducing uric acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m² with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m² with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Plasma FRAP</title>
          <description>Ferric-Reducing Antioxidant Potential</description>
          <units>mmol Fe⁺² · Lˉ¹</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.02"/>
                    <measurement group_id="O2" value="1.39" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AFTER Rasburicase Plasma FRAP (Fe⁺² · Lˉ¹)</title>
        <description>Ferric-Reducing Antioxidant Potential</description>
        <time_frame>12 hours after reducing uric acid</time_frame>
        <population>AFTER rasburicase plasma FRAP only measured in subjects with high uric acid</population>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects With Normal Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
          </group>
          <group group_id="O2">
            <title>Obese Subjects With High Uric Acid</title>
            <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
          </group>
        </group_list>
        <measure>
          <title>AFTER Rasburicase Plasma FRAP (Fe⁺² · Lˉ¹)</title>
          <description>Ferric-Reducing Antioxidant Potential</description>
          <population>AFTER rasburicase plasma FRAP only measured in subjects with high uric acid</population>
          <units>mmol Fe⁺² · Lˉ¹</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.42" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Obese Subjects With Normal Uric Acid</title>
          <description>Subjects with a body mass index = or &gt; 30 kg/m2 with normal uric acid (= or &lt; 5 mg/dL)</description>
        </group>
        <group group_id="E2">
          <title>Obese Subjects With High Uric Acid</title>
          <description>Subjects with a body mass index = or &gt; 30 kg/m2 with high uric acid (&gt;6 mg/dL)
Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Rasburicase: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elisa Fabbrini, MD, PhD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-8156</phone>
      <email>efabbrini@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

